Envoy Medical (COCH) Q1 2025 earnings summary

Executive summary

• Secured $10 million in additional funding to advance the pivotal clinical trial for the fully implanted Acclaim cochlear implant.

• Completed enrollment of 10 participants in the first stage of the pivotal clinical trial; six activated, four pending activation.

• No serious or unanticipated adverse device effects reported; activations and follow-ups within expected norms.

• Modifications from earlier studies appear to have addressed prior electrical system noise issues.

Financial highlights

• Net revenues decreased by $13,000 year-over-year for Q1 2025, mainly due to lower battery replacement sales from supply chain limitations.

• Cost of goods sold increased by $73,000 year-over-year, driven by higher headcount, new supplier expenses, and inventory reserve adjustments.

• R&D expenses rose by $400,000 year-over-year, reflecting increased headcount and clinical trial costs.

• Sales and marketing expenses increased by $33,000 year-over-year, mainly due to higher headcount, travel, and a new patient engagement program.

• General and administrative expenses decreased by $284,000 year-over-year, primarily due to reduced legal and professional fees.

• Net loss attributable to common stockholders was $6.2 million for Q1 2025, compared to $7.6 million in Q1 2024.

• Cash and cash equivalents stood at $5.3 million as of March 31, 2025.

Outlook and guidance

• Management expresses optimism about the pivotal clinical study's progress and market potential for the fully implanted cochlear implant.

• Forward-looking statements highlight expectations for continued operational improvements, clinical trial milestones, and market acceptance.